No­vo Nordisk ad­dress­es off-la­bel Ozem­pic use as it grap­ples with mul­ti­ple short­ages

On the heels of We­govy sup­ply trou­bles, No­vo Nordisk is re­port­ing a short­age of its di­a­betes treat­ment Ozem­pic which con­tains the same ac­tive in­gre­di­ent, semaglu­tide.

The com­pa­ny told End­points News in an email last week that it’s ex­pe­ri­enc­ing “in­ter­mit­tent sup­ply dis­rup­tions” for the Ozem­pic pen that de­liv­ers 0.25 and 0.5 mg dos­es of the drug, caused by “in­cred­i­ble de­mand cou­pled with over­all glob­al sup­ply con­straints.” On Dec. 7, the Amer­i­can So­ci­ety of Health-Sys­tem Phar­ma­cists re­port­ed short­ages af­fect­ing both the 0.25 mg or 5 mg dos­es, as well as the 1 mg and 2 mg dos­es us­ing var­i­ous pen in­jec­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.